IDEAYA Biosciences, Inc. (FRA:30J)

IDEAYA Biosciences Statistics

Total Valuation

FRA:30J has a market cap or net worth of EUR 2.59 billion. The enterprise value is 1.63 billion.

Market Cap	2.59B
Enterprise Value	1.63B

Important Dates

The next estimated earnings date is Friday, February 13, 2026.

Earnings Date	Feb 13, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	87.67M
Shares Outstanding	n/a
Shares Change (YoY)	+15.78%
Shares Change (QoQ)	+1.38%
Owned by Insiders (%)	0.90%
Owned by Institutions (%)	107.69%
Float	86.87M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	14.13
PB Ratio	2.78
P/TBV Ratio	2.78
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-11.92
EV / Sales	8.84
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-18.18

Financial Position

The company has a current ratio of 12.44, with a Debt / Equity ratio of 0.02.

Current Ratio	12.44
Quick Ratio	12.20
Debt / Equity	0.02
Debt / EBITDA	n/a
Debt / FCF	-0.26
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -14.15% and return on invested capital (ROIC) is -11.26%.

Return on Equity (ROE)	-14.15%
Return on Assets (ROA)	-10.77%
Return on Invested Capital (ROIC)	-11.26%
Return on Capital Employed (ROCE)	-18.64%
Revenue Per Employee	1.40M
Profits Per Employee	-1.05M
Employee Count	131
Asset Turnover	0.18
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +20.47% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+20.47%
50-Day Moving Average	25.88
200-Day Moving Average	20.30
Relative Strength Index (RSI)	66.60
Average Volume (20 Days)	98

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	6.49

Income Statement

In the last 12 months, FRA:30J had revenue of EUR 183.10 million and -137.00 million in losses. Loss per share was -1.55.

Revenue	183.10M
Gross Profit	-130.79M
Operating Income	-178.03M
Pretax Income	-137.00M
Net Income	-137.00M
EBITDA	-175.86M
EBIT	-178.03M
Loss Per Share	-1.55

Balance Sheet

The company has 670.67 million in cash and 23.22 million in debt, giving a net cash position of 945.72 million.

Cash & Cash Equivalents	670.67M
Total Debt	23.22M
Net Cash	945.72M
Net Cash Per Share	n/a
Equity (Book Value)	930.74M
Book Value Per Share	10.62
Working Capital	629.12M

Cash Flow

In the last 12 months, operating cash flow was -87.15 million and capital expenditures -2.67 million, giving a free cash flow of -89.83 million.

Operating Cash Flow	-87.15M
Capital Expenditures	-2.67M
Free Cash Flow	-89.83M
FCF Per Share	n/a

Margins

Gross margin is -71.43%, with operating and profit margins of -97.23% and -74.82%.

Gross Margin	-71.43%
Operating Margin	-97.23%
Pretax Margin	-74.82%
Profit Margin	-74.82%
EBITDA Margin	-96.04%
EBIT Margin	-97.23%
FCF Margin	n/a

Dividends & Yields

FRA:30J does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-15.78%
Shareholder Yield	-15.78%
Earnings Yield	-5.29%
FCF Yield	-3.47%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:30J has an Altman Z-Score of 12.62 and a Piotroski F-Score of 3.

Altman Z-Score	12.62
Piotroski F-Score	3